Second, In The "Power Alley" Lobby Series: Pfizer Still Leads In Overall Lobby Spending -- Across Three Prior Q1s...

Here is the laundry list of what Pfizer bent legislative and agency ears, on -- during the first 90 days of Tangerine 2.0's time in office. Again.

The themes do broadly echo those seen at Merck, in our post of last evening -- but these efforts are deeper (and also more focused on blunting tariff talk -- thus more expensive -- reaching down to staffers of Congress-critters, for example). Here's all that -- without any additional ado:

. . .H. Con. Res. 14 -- Establishing the congressional budget [i.e., the Trump 2.0 administration wish list] for the US Government for FY 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034 Budget Reconciliation. . . .

[US House] S 526 - Pharmacy Benefit Manager Transparency Act of 2025; S 527 - Prescription Pricing for the People Act of 2025; S 832 - EPIC Act of 2025; S 864 - HELP Copays Act; S 882 - Patients Before Middlemen Act; S 1040 - Drug Competition Enhancement Act; HR 946 - ORPHAN Cures Act; HR 1492 - EPIC Act; Biosimilars Access & Reimbursement; 340B Reform; 340B Access Act; Inflation Reduction Act (IRA) Biosimilar Pause; Inflation Reduction Act (IRA) Pill Penalty; Vaccine Coverage; Intellectual Property Protections; PBM Reform; Lower Cost More Transparency Act; Bayh-Dole Act March-In Rights; Cancer Policies; Drug Pricing/Foreign Reference Pricing; Digital Therapeutics Access & Reimbursement; Patient Out of Pocket Costs. . . .

[Senate] S 526 - Pharmacy Benefit Manager Transparency Act of 2025; S 527 - Prescription Pricing for the People Act of 2025; S 832 - Epic Act of 2025; S 864 - HELP Copays Act; S 882 - Patients Before Middlemen Act; HR 946 - ORPHAN Cures Act; PBM Reform; Medicaid Prescription Drug Access. . . .

[Both -- taxation] H. Con. Res. 14 - Establishing the congressional budget for the US Government for FY 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034; VICP Reform and Excise Tax; Tax Cuts and Jobs Act (TCJA); Comprehensive Corporate Tax Reform. . . .

HR 2213 - Authorize the President to Enter Into Trade Agreements for the Reciprocal Elimination of Duties or Other Import; Restrictions with Respect to Medical Goods; Medical Supply Chain Resiliency Act; International Supply Chain; Tariffs; Non-Tariff Trade Barriers. . . .

Now you know. [Note that there are bills in Congress to now grant Trump authority to reduce older tariffs; and. . . note to the wise: he needs the same to. . . increase them.] And Pfizer's spend is here declining slightly from 2023 Q1 (i.e., before the election year) -- but it is still the leader of the pack in the USA, for pharma spend.

नमस्ते